What Next For Medtech And Investors Post-Coronavirus?
If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.
You may also be interested in...
Post-Brexit planning is now fully back on the agenda in the UK, and work to shape its post-EU medtech regulatory future is also restarting.
With the World Health Organization pressing for an inquiry into the coronavirus pandemic, it is clear that lessons must be learned for how future global public health emergencies must be handled. Medical technology has played a key role in halting the speed of the pandemic, but why has it taken an episode like COVID-19 for medtech’s true value to be recognized? ZS principal Brian Chapman says things must never go back to where they were.
Surveillance and track-and-trace have emerged as the new focus of the UK’s COVID-19 control strategy, but a workable plan is yet to crystalize.